# ðŸ’° ROI Analysis  
## Clinical Trial Adverse Event (AE) Classifier

---

# ðŸ“Œ Executive Summary

This document presents a **conservative, industry-realistic ROI analysis** for implementing an AI-powered Clinical Trial Adverse Event Classifier in a large pharmaceutical organization.

The model reduces manual effort, accelerates safety signal detection, improves compliance posture, and delivers strong financial returns within the first year.

---

# 1ï¸âƒ£ Baseline Assumptions (Large Pharma Operations)

## Annual Trial Volume

- Active clinical trials: **50**
- Average AEs per trial: **3,000**

### Total AEs per Year

```
50 Ã— 3,000 = 150,000 AEs
```

---

## Current Manual Effort

- Avg time per AE (triage + MedDRA coding + QC): **20 minutes**

### Total Manual Hours

```
150,000 Ã— 20 minutes = 3,000,000 minutes
= 50,000 hours
```

---

## Blended Labor Cost

- Safety case processors
- PV scientists
- QC reviewers

**Fully loaded cost: $80/hour**

---

## Current Annual Manual Cost

```
50,000 hours Ã— $80 = $4,000,000 per year
```

---

# 2ï¸âƒ£ Impact of AI-Powered AE Classifier

## Conservative AI Performance

- 50% time reduction per AE
- Human review retained
- No automated medical judgment
- Regulatory-safe implementation

---

## New Effort

- New time per AE: **10 minutes**

### New Total Hours

```
150,000 Ã— 10 minutes = 25,000 hours
```

---

## Direct Labor Savings

```
25,000 hours Ã— $80 = $2,000,000 per year
```

âœ… Hard, defensible savings.

---

# 3ï¸âƒ£ Additional Business Value (Often Larger Than Labor)

## A. Faster Safety Signal Detection

Assumption:
- Prevents 1 major protocol amendment per year

Typical cost of amendment:
- $300,000 â€“ $600,000  
Use conservative estimate:

```
$300,000
```

---

## B. Reduced Trial Delays

Avoiding 1-week delay in 1 Phase III trial:

Industry average delay cost:
- $100,000/day (conservative)

```
$100,000 Ã— 5 days = $500,000
```

---

## C. Improved Inspection Readiness

Value drivers:
- Fewer audit findings
- Lower remediation effort
- Reduced regulatory exposure

Conservative annual value:

```
$200,000
```

---

## Total Additional Value

```
$300,000
+ $500,000
+ $200,000
= $1,000,000 per year
```

---

# 4ï¸âƒ£ Total Annual Benefit

| Category                          | Annual Value |
|-----------------------------------|-------------|
| Labor Savings                     | $2,000,000  |
| Operational & Risk Reduction      | $1,000,000  |
| **Total Annual Benefit**          | **$3,000,000** |

---

# 5ï¸âƒ£ Investment Cost (Year 1)

## One-Time Implementation Costs

| Item                                | Cost        |
|------------------------------------|------------|
| Data preparation & labeling        | $300,000   |
| Model development & validation     | $400,000   |
| GxP documentation (IQ/OQ/PQ)       | $200,000   |
| System integration (CTMS, safety)  | $200,000   |
| **Total One-Time Cost**            | **$1,100,000** |

---

## Annual Run Costs

| Item                          | Cost       |
|-------------------------------|-----------|
| Cloud & inference             | $200,000  |
| Monitoring & retraining       | $150,000  |
| Support & governance          | $150,000  |
| **Total Annual Run Cost**     | **$500,000** |

---

# 6ï¸âƒ£ ROI Calculation

## Year 1

### Total Benefit

```
$3,000,000
```

### Total Cost

```
$1,100,000 + $500,000 = $1,600,000
```

### Net Benefit

```
$3,000,000 - $1,600,000 = $1,400,000
```

---

## ROI Formula

```
ROI = (Net Benefit / Total Cost) Ã— 100
ROI = (1,400,000 / 1,600,000) Ã— 100
â‰ˆ 87.5%
```

---

## Payback Period

Estimated payback:

```
6â€“8 months
```

---

# 7ï¸âƒ£ Year 2+ ROI (Where It Becomes Highly Attractive)

No one-time costs remain.

### Annual Benefit

```
$3,000,000
```

### Annual Cost

```
$500,000
```

### Net Annual Value

```
$2,500,000
```

---

## Ongoing ROI

```
ROI = (2,500,000 / 500,000) Ã— 100
= 500%
```

---

# 8ï¸âƒ£ Executive Messaging (Leadership-Ready Narrative)

### Key Positioning

> "Even with conservative assumptions and mandatory human review, the AE classifier delivers payback within the first year, reduces safety risk, and scales across the entire trial portfolio. The largest value driver is earlier signal detection and improved inspection readiness â€” not just labor reduction."

---

## Emphasize

- Conservative assumptions
- Compliance-first design
- No automation of medical judgment
- Human-in-the-loop model
- Portfolio-level scalability
- Risk mitigation benefits

---

# 9ï¸âƒ£ Sensitivity Analysis

| Time Reduction Scenario | Estimated ROI |
|-------------------------|--------------|
| 30% reduction           | ~45%         |
| 50% reduction           | ~88%         |
| 65% reduction           | >120%        |

---

# ðŸ”Ž Strategic Impact

Beyond cost savings, the AE Classifier:

- Accelerates safety signal detection
- Reduces regulatory risk exposure
- Improves inspection readiness
- Enhances data consistency
- Supports scalable trial expansion
- Enables proactive risk management

---

# ðŸ“Š Conclusion

The Clinical Trial AE Classifier is:

- Financially defensible
- Operationally transformative
- Compliance-aligned
- Scalable across portfolios

With first-year ROI of ~88% and 500%+ ongoing ROI, this represents a high-impact, low-regret investment for modern clinical operations.

---

ðŸš€ Transforming Pharmacovigilance Through AI-Driven Efficiency
